Search results
Zealand Pharma AS (ZEAL) Stock Jumps 9.1%: Will It Continue to Soar?
Zacks via Yahoo Finance· 2 years agoZealand Pharma AS (ZEAL) witnessed a jump in share price last session on above-average trading...
Zealand Pharma A/S (ZLDPF) Is a Great Choice for 'Trend' Investors, Here's Why
Zacks via Yahoo Finance· 1 year agoZealand Pharma A/S (ZLDPF) could be a great choice for investors looking to make a profit from...
Zealand Pharma, Novo Nordisk Ink Licensing Pact For Drug To Lower Blood Sugar Levels
Benzinga via Yahoo Finance· 2 years agoZealand Pharma A/S (NASDAQ: ZEAL) has entered into a global license and development agreement with...
Novo Nordisk faces competition close to home as Danish rival Zealand Pharma’s shares jump 35% on...
Fortune via AOL· 3 months agoNovo Nordisk has been riding a wave of success following the hit of its weight-loss drug Wegovy,...
Health Care Roundup: Market Talk
The Wall Street Journal· 2 weeks agoNEWSPLUS The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET. 0501 ET...
7 Sorry Pharma Stocks to Sell in April Before It’s Too Late
InvestorPlace via Yahoo Finance· 1 year agoFinding the best pharma stocks to sell can be an all-or-nothing kind of business. If you score on a...
Missed Out on Novo Nordisk? This Much Smaller Danish Biotech Could Be the Next Hot Weight-Loss...
Motley Fool via Yahoo Finance· 3 months agoA big focus for healthcare companies recently has been on the weight-loss industry. It's no...
Weight-Loss Tizzy: Why Altimmune Surged 23% As Others Tumbled On A New Study
Investor's Business Daily· 3 months agoBiotech stocks Akero Therapeutics and Altimmune, diverged Monday as Wall Street debated the outcome...
Analysts Expect Breakeven For Mayne Pharma Group Limited (ASX:MYX) Before Long
Simply Wall St. via Yahoo Finance· 3 months agoMayne Pharma Group Limited (ASX:MYX) is possibly approaching a major achievement in its business, so...
Verve Stock Soars On $250 Million Eli Lilly Deal
Investor's Business Daily· 7 months agoPharma behemoth Eli Lilly will pay $250 million upfront for the rights to three gene-editing drugs from Verve Therapeutics, the companies said Tuesday....
